{
    "id": 10702,
    "fullName": "TFG - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TFG-ALK results from the fusion of TFG and ALK, and leads to constitutive Alk phosphoryltaion, cell transformation in culture, and tumorigenisis in animal models (PMID: 10556217, PMID: 15208656). TFG-ALK fusions have been identified in anaplastic large cell lymphoma and inflammatory myofibroblastic tumors (PMID: 27874193).",
            "references": [
                {
                    "id": 11167,
                    "pubMedId": 15208656,
                    "title": "Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15208656"
                },
                {
                    "id": 15868,
                    "pubMedId": 27874193,
                    "title": "ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27874193"
                },
                {
                    "id": 3511,
                    "pubMedId": 10556217,
                    "title": "TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10556217"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 10342,
        "geneSymbol": "TFG",
        "terms": [
            "TFG",
            "HMSNP",
            "SPG57",
            "TF6",
            "TRKT3"
        ]
    },
    "variant": "TFG - ALK",
    "createDate": "08/18/2015",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15373,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing TFG-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 10718,
                "profileName": "TFG - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15375,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited growth of transformed cells expressing TFG-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 10718,
                "profileName": "TFG - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15372,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing TFG-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 10718,
                "profileName": "TFG - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15374,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ensartinib (X-396) inhibited growth of transformed cells expressing TFG-ALK in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 10718,
                "profileName": "TFG - ALK"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15134,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Tagrisso (osimertinib), and EGFR C797G, C797S, L858R, L781Q, T790M, and TFG-ALK were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30781,
                "profileName": "TFG - ALK EGFR L718Q EGFR T790M EGFR C797G EGFR C797S EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10718,
            "profileName": "TFG - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 17577,
                    "name": "ALK Inhibitor",
                    "profileName": "TFG - ALK"
                }
            ]
        },
        {
            "id": 30781,
            "profileName": "TFG - ALK EGFR L718Q EGFR T790M EGFR C797G EGFR C797S EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}